James Rubenstein, MD, PhD

(415) 502-4430

513 Parnassus Ave, HSE
San Francisco, CA 94143

Visit CTSI Profile

  • Professor, School of Medicine

Displaying 1 - 85 of 85

  1. David A. Solomon, Huimin Geng, Raymond A. Sobel, Lakshmi Subbaraj, Mazie Tsang, James L. Rubenstein. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood. 2019 Nov 13; 134(Supplement_1):1494-1494. View on Pubmed
  2. Damato B, Bever GJ, Kim DJ, Afshar AR, Rubenstein JL. An audit of retinal lymphoma treatment at the University of California San Francisco. Eye (Lond). 2019 Jul 29. View on Pubmed
  3. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:454-466. View on Pubmed
  4. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019 02 19; 21(3):296-305. View on Pubmed
  5. Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019 Jul; 186(1):180-183. View on Pubmed
  6. Huimin Geng, Brice Tiret, Hua-Xin Gao, Cigall Kadoch, Ming Lu, Lingjing Chen, Ilwoo Park, Gerd Melkus, Adam Elkhaled, John Kurhanewicz, Lisa Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, Rana Anjum, Andrew Bloecher, Myriam Chaumeil, James Rubenstein. Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):2840-2840. View on Pubmed
  7. Khoan Vu, James Rubenstein, Gabriel N. Mannis, Jimmy Hwang, Huimin Geng. Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):4230-4230. View on Pubmed
  8. Susan Wu, Steve Braunstein, James Rubenstein, Penny Sneed. RTHP-31. STEREOTACTIC RADIOSURGERY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi231-vi231. View on Pubmed
  9. Rubenstein JL. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leuk Lymphoma. 2019 02; 60(2):281-283. View on Pubmed
  10. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607. View on Pubmed
  11. Damato BE, Bever GJ, Afshar AR, Rubenstein JL. Insights from a Case of Vitreoretinal Lymphoma. Ocul Oncol Pathol. 2019 Jan; 5(1):13-19. View on Pubmed
  12. Rubenstein JL. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):556-564. View on Pubmed
  14. Brice Tiret, Adam Autry, Ilwoo Park, Ming Lu, Rana Anjum, Liza Drew, Sebastien Degorce, Michele Mayo, Keith Dillman, James Rubenstein, Myriam M Chaumeil. EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Neuro-Oncology. 2017 Nov 6; 19(suppl_6):vi88-vi88. View on Pubmed
  15. L. Nayak, F.M. Iwamoto, A.J. Ferreri, A. Santoro, S. Singer, C. Batlevi, T. Batchelor, J. Rubenstein, P. Johnston, R. Ramchandren, C. Soussain, J. Drappatz, K. Becker, M. Witzens-Harig, G. Illerhaus, A. Herrera, A. Masood, M. Shipp. CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. Hematological Oncology. 2017 Jun 1; 35(S2):420-421. View on Pubmed
  16. J.L. Rubenstein, J. Hwang, G. Mannis. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Hematological Oncology. 2017 Jun 1; 35(S2):343-344. View on Pubmed
  17. Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leuk Lymphoma. 2017 11; 58(11):2748-2751. View on Pubmed
  18. Huimin Geng, Huaxin Gao, Cigall Kadoch, Ming Lu, Lingjing Chen, Rana Anjum, Lisa Drew, Sebastien Degorce, Keith Dillman, Michele Mayo, Shawn Anderson, Colin Collins, Clifford A. Lowell, James L. Rubenstein. Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. Blood. 2016 Dec 2; 128(22):777-777. View on Pubmed
  19. Carnevale J, Rubenstein JL. The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am. 2016 Dec; 30(6):1293-1316. View on Pubmed
  20. James Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, Mallory Kock, Wesley Cheung, Phoebe Killea, Kee-Hyun Choi, Xiaomin Wang, Pamela Munster, Bertil Damato. ATIM-27. PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE MAINTENANCE IN RECURRENT CNS LYMPHOMA. Neuro-Oncology. 2016 Nov 1; 18(suppl_6):vi23-vi24. View on Pubmed
  21. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 01; 19(1):99-108. View on Pubmed
  22. James L. Rubenstein, Eleanor Fraser, Paul Formaker, James Chi-Chiang Lee, Nianhang Chen, Mallory Kock, Wesley Cheung, Xiaomin Wang, Pamela N. Munster, Bertil Damato. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):7502-7502. View on Pubmed
  23. Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016 07 07; 128(1):32-6. View on Pubmed
  24. Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! J Clin Oncol. 2016 05 20; 34(15):1829-30. View on Pubmed
  25. Huimin Geng, Zhengshan Chen, Shawn Anderson, Eleanor Fraser, Ming Lu, Chen Lingjing, Colin Collins, Muschen Markus, James L. Rubenstein. Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia. Blood. 2015 Dec 3; 126(23):3900-3900. View on Pubmed
  26. Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR Am J Roentgenol. 2015 Nov; 205(5):1075-85. View on Pubmed
  27. Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatr Hematol Oncol. 2015; 32(8):529-34. View on Pubmed
  28. Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015 Mar; 4(1):11. View on Pubmed
  29. Okimoto RA, Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2. View on Pubmed
  30. James L. Rubenstein, Paul Formaker, Xiaomin Wang, Nianhang Chen, Michael Seider, Pamela Munster, Bertil Damato. Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma. Blood. 2014 Dec 6; 124(21):4470-4470. View on Pubmed
  31. Wang CC, Carnevale J, Rubenstein JL. Progress in central nervous system lymphomas. Br J Haematol. 2014 Aug; 166(3):311-25. View on Pubmed
  32. Rubenstein JL, Cheson BD, Jung SH, Kaplan LD. Reply to M.C. Chamberlain. J Clin Oncol. 2014 Mar 10; 32(8):858-9. View on Pubmed
  33. Agnieszka Korfel, James Rubenstein, German Ott, Eric D. Hsi. CNS Lymphoma. Rare Lymphomas. 2014 Jan 1; 207-223. View on Pubmed
  34. Neel K. Gupta, Jimmy Hwang, James L. Rubenstein. High-Dose Methotrexate Is Effective, Safe, and Leads To Durable Responses In Patients With AIDS-Related Primary Central Nervous System Lymphoma Treated During The Era Of Combined Anti-Retroviral Therapy. Blood. 2013 Nov 15; 122(21):1792-1792. View on Pubmed
  35. Hua-Xin Gao, Shawn Anderson, Cigall Kadoch, Mekhala Maiti, Lingjing Chen, Dong-Han Yao, Gerd Melkus, Maria Wang, Yan Ren, Michael Breider, Carla Heise, Clifford A. Lowell, Colin Collins, James L. Rubenstein. Novel Intracranial Xenografts Of CNS Lymphoma Implicate a Role For Cereblon As a Mediator Of Lenalidomide Efficacy. Blood. 2013 Nov 15; 122(21):374-374. View on Pubmed
  36. Chia-Ching J. Wang, Paige M Bracci, James L. Rubenstein. Obesity and Hepatitis B Infection and Risk Of Primary CNS Lymphoma. Blood. 2013 Nov 15; 122(21):4298-4298. View on Pubmed
  37. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41. View on Pubmed
  38. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013 Oct 03; 122(14):2318-30. View on Pubmed
  39. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013 Jun 06; 121(23):4740-8. View on Pubmed
  40. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 01; 31(25):3061-8. View on Pubmed
  41. Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol. 2013 Mar 01; 70(3):311-9. View on Pubmed
  42. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. View on Pubmed
  43. James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan. BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood. 2012 Nov 16; 120(21):301-301. View on Pubmed
  44. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55. View on Pubmed
  45. James L. Rubenstein. Biology of Primary Central Nervous System Lymphoma. Lymphoma and Leukemia of the Nervous System. 2012 Jan 1; 99-111. View on Pubmed
  46. Francisco Valles, Samuel Regalado, James L. Rubenstein, Soonmee Cha. Combined Diffusion and Perfusion MRI As Biomarkers of Prognosis in Immunocompetent Patients with Primary CNS Lymphoma. Blood. 2011 Nov 18; 118(21):2655-2655. View on Pubmed
  47. Cigall Kadoch, Valerie Wong, Lingjing Chen, Anna Bet-Lachin, Ritu Roy, William Hyun, Caroline Behler, Clifford Lowell, James L. Rubenstein. Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages,. Blood. 2011 Nov 18; 118(21):3219-3219. View on Pubmed
  48. Hua-Xin Gao, Shawn Anderson, Lingjing Chen, Cigall Kadoch, Byron C Hann, Clifford Lowell, Colin Collins, James L. Rubenstein. Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts,. Blood. 2011 Nov 18; 118(21):3477-3477. View on Pubmed
  49. Anna Bet-Lachin, Frank Jiang, Lingjing Chen, Keyvan Keshari, David Wilson, John Kurhanewicz, James L. Rubenstein. Metabolic Profiling of CNS Lymphoma and Its Microenvironment. Blood. 2011 Nov 18; 118(21):588-588. View on Pubmed
  50. James L. Rubenstein, Lingjing Chen, Ranjana Advani, Jan Drappatz, Elizabeth Gerstner, Tracy Batchelor, Hendrikus Krouwer, Cigall Kadoch, Pamela Munster, Soonmee Cha, Marc A Shuman, Lloyd E. Damon. Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood. 2011 Nov 18; 118(21):959-959. View on Pubmed
  51. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011; 16(11):1589-99.
  52. Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011 Jul 10; 29(20):e595-7.
  53. James L. Rubenstein, Jeffrey L. Johnson, Sin-Ho Jung, Bruce D. Cheson, Lawrence D. Kaplan. Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202. Blood. 2010 Nov 19; 116(21):763-763.
  54. J. L. Rubenstein, C. Kadoch, V. S. Wong, W. Hyun, C. Lowell. Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. Journal of Clinical Oncology. 2010 May 20; 28(15_suppl):2532-2532.
  55. Cigall Kadoch, Valerie D. Wong, Tara Rambaldo, William Hyun, Clifford Lowell, James Rubenstein. Macrophage Polarization and Acquired Resistance to Rituximab in CNS Lymphoma. Blood. 2009 Nov 20; 114(22):3749-3749.
  56. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009 Jul; 6(3):587-97.
  57. James L. Rubenstein, Lingjing Chen, Cigall Kadoch, Sushmita Roy, Chris Becker, Howard Schulman. Reply to H. Zetterberg et al. Journal of Clinical Oncology. 2009 May 1; 27(13):2303-2304.
  58. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97.
  59. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 01; 113(1):266-7; author reply 267-8.
  60. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep. 2009 Jan; 11(1):73-80.
  61. Yang I, Delpolyi A, Sughrue ME, Rubenstein J, Bollen AW, Parsa AT. Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis. J Neurooncol. 2009 Jan; 91(1):113-6.
  62. Penny K. Sneed, Norbert Kased, Kim Huang, James L. Rubenstein. Chapter 56 Brain Metastases and Neoplastic Meningitis. Abeloff\u0027s Clinical Oncology. 2008 Jan 1; 827-844.
  63. Rubenstein J, Ferreri AJ, Pittaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:43-51.
  64. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 01; 26(1):96-105.
  65. Cigall Kadoch, Marc A. Shuman, James L. Rubenstein. Complement Activation and Resistance within the Cerebrospinal Fluid Following Intraventricular Administration of Anti-CD20 in the Treatment of Recurrent CNS Lymphoma. Blood. 2007 Nov 16; 110(11):3418-3418.
  66. Samar Issa, Arthur Shen, Jon Karch, Cigall Kadoch, Marc Shuman, Lloyd Damon, James Rubenstein. Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis. Blood. 2007 Nov 16; 110(11):1364-1364.
  67. James Rubenstein, Lauren Abrey, Ranjana Advani, Marc Shuman, Tony Tsai, Joan O'Brien. In Reply. Journal of Clinical Oncology. 2007 Oct 1; 25(28):4509-4511.
  68. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6.
  69. Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006 Nov 15; 21(5):E1.
  70. James L. Rubenstein, Cigall Kadoch, Jon Karch, Andrew Josephson, Samar Issa, Chris Becker, Howard Schulman, Lloyd Damon, Marc A. Shuman, Sushmita Roy. Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma. Blood. 2006 Nov 1; 108(11):2036-2036.
  71. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 01; 107(9):3716-23.
  72. Orr JW, Dosoretz DD, Mahoney D, Roland PY, Kelly FJ, Blitzer P, Nakfoor B, Katin M, Rubenstein J, Boothby RR. Surgically (laparotomy/laparoscopy) guided placement of high dose rate interstitial irradiation catheters (LG-HDRT): technique and outcome. Gynecol Oncol. 2006 Jan; 100(1):145-8.
  73. Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am. 2005 Aug; 19(4):705-17, vii.
  74. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005 Apr 01; 23(10):2233-9.
  75. J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004 Jul 15; 22(14_suppl):6593-6593.
  76. J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004 Jul 15; 22(14_suppl):6593-6593.
  77. Philip V. Theodosopoulos, James L. Rubenstein, Michael W. McDermott. Brain Metastases from Genitourinary Cancer: Germ Cell, Testicular, Prostate and Bladder Cancer. Intracranial Metastases. 2004 Jan 1; 352-361.
  78. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003 Jan 15; 101(2):466-8.
  79. Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M. Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol. 2002 May; 58(1):53-6.
  80. Marín O, Yaron A, Bagri A, Tessier-Lavigne M, Rubenstein JL. Sorting of striatal and cortical interneurons regulated by semaphorin-neuropilin interactions. Science. 2001 Aug 03; 293(5531):872-5.
  81. Hevner RF, Shi L, Justice N, Hsueh Y, Sheng M, Smiga S, Bulfone A, Goffinet AM, Campagnoni AT, Rubenstein JL. Tbr1 regulates differentiation of the preplate and layer 6. Neuron. 2001 Feb; 29(2):353-66.
  82. Pleasure SJ, Anderson S, Hevner R, Bagri A, Marin O, Lowenstein DH, Rubenstein JL. Cell migration from the ganglionic eminences is required for the development of hippocampal GABAergic interneurons. Neuron. 2000 Dec; 28(3):727-40.
  83. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000 Jul-Aug; 2(4):306-14.
  84. Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Grosschedl R. Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development. 2000 Feb; 127(3):469-82.
  85. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL, German MS. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development. 1998 Jun; 125(12):2213-21.